Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21951968 | 0.86 | ALDH1A1 (0.60) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL21951961 | 0.85 | GLO1 (0.53) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL8978522 | 0.81 | ALDH1A1 (0.73) | ALDH1A1PKMKDM4EHSD17B10GFER | |
| SCHEMBL8978544 | 0.76 | ALDH1A1 (1.00) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL24176313 | 0.76 | HAGH (0.73) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL8978574 | 0.71 | ALDH1A1 (0.68) | ALDH1A1PKMKDM4EHSD17B10GFER | |
| SCHEMBL13983883 | 0.71 | ALDH1A1 (0.68) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL8978554 | 0.70 | TDP1 (0.56) | ALDH1A1PKMKDM4EALOX15HSD17B10 | |
| SCHEMBL24176022 | 0.70 | TDP1 (0.51) | ALDH1A1KDM4EALOX15HSD17B10GFER | |
| SCHEMBL21964209 | 0.69 | ALDH1A1 (0.64) | ALDH1A1PKMKDM4EALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000841-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIVERSITÉ DE MONTPELLIER (FR) | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000841-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, LCT, MGAM2 | ALDH1A1 547/4885PKM 2542/4885KDM4E 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.